MannKind Corporation (MNKD)

MannKind: New Approvals Majorly Increase MannKind's Prospects

MannKind Corporation (MNKD) Q2 2026 Earnings Call Transcript

MannKind Q2 Earnings Call Highlights

Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key Metrics

MannKind (MNKD) Reports Q2 Loss, Beats Revenue Estimates

MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update

MannKind Corporation (MNKD) Discusses Phase 1b Results and Clinical Progress of Nintedanib DPI for IPF Transcript

MannKind's Inhaled IPF Drug Clears Phase 1b Safety Hurdle, Phase 2 Underway

MannKind injection helps heart failure patients avoid ER infusions

MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF

MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026

MannKind (NASDAQ:MNKD) Shares Gap Up – Still a Buy?

FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease

MannKind Corporation (MNKD) Discusses FDA Approval of Furoscix ReadyFlow for IV-Equivalent Diuretic Therapy in Fluid Overload Transcript

MannKind Wins FDA Approval for Furoscix ReadyFlow, Secures $50M PIPE

MannKind Announces $50 Million Private Placement

MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease

What This MannKind Filing Reveals About Three Years of Underperformance

What This MannKind Director Sale Signals With $32.7 Million in Quarterly Royalties Revenue Potentially at Risk

What This MannKind Sale Signals With Tyvaso Royalties at $32.7 Million